Medtech contract manufacturer Life Science Outsourcing Inc. (LSO) announced today that it has acquired J-Pac Medical, a supplier of manufacturing, packaging, and sterilization services to medical device and diagnostics companies.
Headquartered in Somersworth, NH, J-Pac Medical’s experience in complex thermoplastic devices, packaging, and in-house tooling capabilities allows it to manufacture anatomically correct, Class III implantable textile assemblies, lab-on-chip reagent blisters, and sophisticated thermoformed packaging. It operates a 60,000-square-foot, ISO 13485–certified and FDA-registered facility with cleanroom capabilities in New Hampshire. It also maintains strong supplier relationships in Costa Rica's medical manufacturing hub.
"J-Pac Medical stood out as a unique and attractive business that aligned perfectly with LSO's strategic and commercial objectives,” said LSO CEO John Nino. “The company's capabilities in reagent blister packaging, thermoforming, and biomaterials will be additive to LSO's existing customer base.”
"J-Pac Medical's technical know-how and production experience around reagent blister packaging in the molecular diagnostics end-market represents an exciting growth opportunity given trends in point-of-care diagnostics, specifically as it relates to microfluidics and lab-on-chip applications,” said Jeff Barrett, President of the newly formed Diagnostics Division. “Our partnership with LSO broadens our reach within the life sciences and diagnostics end-markets we are targeting.”
Located in Brea, CA, LSO was acquired by private equity firm PPC Enterprises LLC in January 2021. This acquisition further builds on the vision of a truly national platform that provides post-manufacturing and regulated services to early stage and established medtech and diagnostics companies, commented Asif Zaman, Partner and Head of Healthcare Services at PPC.
"The combination of LSO and J-Pac Medical allow us to provide a wider array of services to our customers across an even broader geographic footprint,” added PPC Partner John Morgan. “This should allow a greater number of medical device and diagnostics organizations to accelerate their development and manufacturing capabilities.”